간세포암 환자에서 Regorafenib 복용 후 발생한 수족 피부 반응과 음낭 피부염 1예

초록

Regorafenib is an oral multikinase inhibitor used to treat advanced solid tumors, including hepatocellular carcinoma (HCC), gastrointestinal stromal tumors, and colorectal cancer. Adverse dermatological reactions are common after regorafenib treatment. The most frequent cutaneous adverse reaction is hand-foot skin reaction (HFSR). Compared to HFSR, reports on adverse reactions on the scrotum associated with regorafenib are limited. Only a few cases of adverse reactions on the scrotum associated with HFSR have been reported. We present the case of a 55-year-old male patient with a 1-year history of scrotal dermatitis and HFSR, who had been undergoing treatment for HCC. One year after administration of oral regorafenib (160 mg/d), multiple vesicles, pustules, desquamation, and hyperkeratosis developed on both hands and feet, accompanied by scaly erythematous plaques around the scrotum. The lesions improved after two weeks of treatment with topical and systemic steroids. Herein, we report a rare case of scrotal dermatitis associated with regorafenib-induced HFSR.

키워드